Effectiveness, Safety, and Side Effect of Depo Progestin and Depo Vigestron Contraception
Downloads
Methods: This study used randomized controlled clinical trial and open label. The research subject were 900 people in two center, Surabaya and Palembang. The samples were divided into 3 (three) groups, group Depo Progestin® vial 3 ml, group Depo Vigestron® vial 3 ml, and group Depo Vigestron® vial 1 ml. Each of consist 300 women using the "random permutation block". Analysis was performed 5 times, when an initial injection and a schedule of repeated injections in the 3rd, 6th, 9th and 12th month. The data analyzed include weight, blood pressure, menstrual pattern, and the complaints of the patients.
Results: From the 900 only 862 valid samples. The results showed no signi fi cant difference between groups Depo Progestin® 3ml, Depo Vigestron® 3 ml and Depo Vigestron® 1 ml. The majority of respondents experienced an increase in weight, but still within normal limits, did not have increased blood pressure, increased menstrual blood volume, Pregnancy didn't occured to all respondents and found no abnormalities in cervical cytology.
Conclusion: Contraceptive injection of Depo Progestin® 3 ml, Depo Vigestron® 3 ml dan Depo Vigestron® 1 ml, have used during 12 months can be concluded that those tree kind of contraception were efective, safe and had no side effect.
Affandi, Biran, 1990. Kontrasepsi Bulanan Kombinasi 25 mg Medroksi Progesteron Acetat dan 5 mg Estradiol Sipionate. Disampaikan pada loakarya Penelitian Pilot Suntikan KB, Bulanan Cyclofem, BKKBN Pusat, Jakarta 12–14 Februari 1990
Chinnatamby S., 1971. A comparison of the long-acting contraceptive agents norethisterone oenanthate and medroxyprogesterone acetate. Aust NZ J Obstet Gynaecol: 11: 233–6.
El Mahgoub, S., 1980. Body weight and cycle control of injectable contraceptives. J Reprod Med; 24: 119–26
Fajumi, JO., 1983. Alterations in blood lipid and side effects induced by Depo Provera in Nigerian women. Contraception; 27: 161–75.
Fraser, IS, Dennerstein GJ., 1994. DepoProvera in an Australian metropolitan practice. Med J; 160: 553–6.
Authors who publish with Jurnal Ners agree to the following terms:
- Authors transfer the Copyright and grant Jurnal Ners the right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to remix, adapt and build upon the work with an acknowledgment of the work's authorship and of the initial publication in Jurnal Ners.
- Authors are permitted to copy and redistribute the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Jurnal Ners.
Jurnal Ners requires a formal written declaration and transfer of copyright from the author(s) for each article published. We, therefore, ask you to complete and return this form, retaining a copy for your own records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication. The form can be downloaded HERE.
